Q4 FY2026 EarningsQ4 FY26 results significantly beat consensus across top and bottom lines, with revenue reaching $16.1M vs. $12.3M expected. GAAP EPS of ($0.00) substantially outperformed the forecasted ($0.33) loss, driven by a $1.0M derivative gain and the successful launch of EXXUA, which contributed $3.9M in its first full quarter. Despite a slight miss in gross margin (64.6% vs. 65.3% expected), the company achieved a record cash balance of $26.3M following a warrant restructuring that improved stockholders' equity by $26.4M.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Aytu BioPharma(AYTU) the Revenue is 16.11 M (+6.42%), Beat estimate;the EBIT is -777 K (+89.81%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.02B6.42%
0.01B18.89%
+0.00B25.31%
EBITExceed expectations
-0.00B89.81%
-0.00B39.98%
+0.00B49.83%
EPS
TBA--
-0.32588.87%
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf